DE602004027141D1 - Produktion von poxviren mit adhärenten oder nicht adhärenten vogelzellinien - Google Patents

Produktion von poxviren mit adhärenten oder nicht adhärenten vogelzellinien

Info

Publication number
DE602004027141D1
DE602004027141D1 DE602004027141T DE602004027141T DE602004027141D1 DE 602004027141 D1 DE602004027141 D1 DE 602004027141D1 DE 602004027141 T DE602004027141 T DE 602004027141T DE 602004027141 T DE602004027141 T DE 602004027141T DE 602004027141 D1 DE602004027141 D1 DE 602004027141D1
Authority
DE
Germany
Prior art keywords
poxviruses
adherences
adherent
production
cell lines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004027141T
Other languages
German (de)
English (en)
Inventor
Fabienne Guehenneux
Bertrand Pain
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vivalis SA
Original Assignee
Vivalis SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP03291813A external-priority patent/EP1500699A1/en
Application filed by Vivalis SA filed Critical Vivalis SA
Publication of DE602004027141D1 publication Critical patent/DE602004027141D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24151—Methods of production or purification of viral material
    • C12N2710/24152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE602004027141T 2003-07-22 2004-07-22 Produktion von poxviren mit adhärenten oder nicht adhärenten vogelzellinien Expired - Lifetime DE602004027141D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03291813A EP1500699A1 (en) 2003-07-22 2003-07-22 Production of vaccinia virus with adherent or non adherent avian cell lines
FR0314389 2003-12-09
PCT/IB2004/002621 WO2005007840A1 (en) 2003-07-22 2004-07-22 Production of poxviruses with adherent or non adherent avian cell lines

Publications (1)

Publication Number Publication Date
DE602004027141D1 true DE602004027141D1 (de) 2010-06-24

Family

ID=34081825

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004027141T Expired - Lifetime DE602004027141D1 (de) 2003-07-22 2004-07-22 Produktion von poxviren mit adhärenten oder nicht adhärenten vogelzellinien

Country Status (14)

Country Link
US (3) US7432101B2 (enExample)
EP (2) EP1646715B1 (enExample)
JP (2) JP4787156B2 (enExample)
KR (1) KR101121971B1 (enExample)
AT (1) ATE467678T1 (enExample)
AU (1) AU2004257939B2 (enExample)
CA (1) CA2531565C (enExample)
DE (1) DE602004027141D1 (enExample)
DK (1) DK1646715T3 (enExample)
ES (1) ES2345820T3 (enExample)
PL (1) PL1646715T3 (enExample)
PT (1) PT1646715E (enExample)
SI (1) SI1646715T1 (enExample)
WO (1) WO2005007840A1 (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7445924B2 (en) * 2000-11-23 2008-11-04 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant and cultivation method
FR2836924B1 (fr) * 2002-03-08 2005-01-14 Vivalis Lignees de cellules aviaires utiles pour la production de substances d'interet
ES2305514T5 (es) * 2002-09-05 2019-06-14 Bavarian Nordic As Método para la amplificación de un poxvirus en condiciones exentas de suero
PL1646715T3 (pl) * 2003-07-22 2010-10-29 Valneva Wytwarzanie pokswirusów za pomocą linii adherentnych lub nieadherentnych komórek ptasich
EP1528101A1 (en) 2003-11-03 2005-05-04 ProBioGen AG Immortalized avian cell lines for virus production
FR2884255B1 (fr) 2005-04-11 2010-11-05 Vivalis Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe
AU2011253998B2 (en) * 2005-04-11 2014-04-24 Valneva Process of manufacturing viral vaccines in suspension avian embryonic derived stem cell lines
FR2898909A1 (fr) 2006-03-24 2007-09-28 Agronomique Inst Nat Rech Combinaison de marqueurs de cellules aviaires
WO2007135133A1 (en) * 2006-05-19 2007-11-29 Vivalis Avian cell lines derived from primordial germ cells useful for the production of substances of interest
HUE037866T2 (hu) 2006-06-20 2018-09-28 Transgene Sa Eljárás poxvírusok és poxvírus-készítmények elõállítására
CN101506354B (zh) * 2006-08-09 2014-05-07 瓦内瓦公司 用胚胎干细胞制备转基因禽类的方法
EP2129764B1 (en) * 2007-03-05 2018-10-10 Terumo BCT, Inc. Cell expansion system and methods of use
EP1985305A1 (en) * 2007-04-24 2008-10-29 Vivalis Duck embryonic derived stem cell lines for the production of viral vaccines
RU2475536C2 (ru) 2007-07-03 2013-02-20 Трансген С.А. Иммортализованная клеточная линия птиц
US8357531B2 (en) 2007-07-03 2013-01-22 Transgene S.A. Immortalized avian cell lines
PL214884B1 (pl) * 2008-09-29 2013-09-30 Inst Immunologii I Terapii Doswiadczalnej Pan Test ELISA do wykrywania w surowicy bydlecej przeciwcial przeciwko antygenowi powierzchniowemu gp51 BLV
US9181341B2 (en) 2009-01-19 2015-11-10 Innate Pharma Anti-KIR3D antibodies
EP2393922A1 (en) * 2009-02-06 2011-12-14 GlaxoSmithKline Biologicals S.A. Purification of virus or viral antigens by density gradient ultracentrifugation
BRPI1007744A2 (pt) 2009-05-12 2017-06-27 Transgene Sa método para a produção e purificação de um ortopoxvírus do tipo selvagem, ortopoxvírus do tipo selvagem, composição farmacêutica, uso de um ortopoxvírus do tipo selvagem e uso de uma linhagem de células aviárias imortalizadas
WO2012010280A1 (en) 2010-07-20 2012-01-26 Bavarian Nordic A/S Method for harvesting expression products
SG10201509953VA (en) * 2010-09-07 2016-01-28 Technion Res & Dev Foundation Novel Methods And Culture Media For Culturing Pluripotent Stem Cells
EP2625264B1 (en) 2010-10-08 2022-12-07 Terumo BCT, Inc. Methods and systems of growing and harvesting cells in a hollow fiber bioreactor system with control conditions
EP2660316A1 (en) 2012-05-02 2013-11-06 Helmholtz-Zentrum für Infektionsforschung GmbH Avian cell line and its use in production of protein
US20140255447A1 (en) * 2013-03-05 2014-09-11 Biomune Company Production of avian embryo cells
EP3068866B1 (en) 2013-11-16 2018-04-25 Terumo BCT, Inc. Expanding cells in a bioreactor
WO2015148704A1 (en) 2014-03-25 2015-10-01 Terumo Bct, Inc. Passive replacement of media
US10077421B2 (en) 2014-04-24 2018-09-18 Terumo Bct, Inc. Measuring flow rate
US20160090569A1 (en) 2014-09-26 2016-03-31 Terumo Bct, Inc. Scheduled Feed
KR102507483B1 (ko) 2014-12-01 2023-03-07 트랜스진 안정한 액체 백시니아 바이러스 제제
WO2016088243A1 (ja) * 2014-12-05 2016-06-09 株式会社ニコン 判定装置、観察システム、観察方法、そのプログラム、細胞の製造方法、および細胞
CN107949397A (zh) 2015-02-13 2018-04-20 特兰斯吉恩股份有限公司 免疫治疗疫苗和抗体组合治疗
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
WO2017191147A1 (en) 2016-05-04 2017-11-09 Transgene Sa Combination therapy with cpg tlr9 ligand
WO2017205667A1 (en) 2016-05-25 2017-11-30 Terumo Bct, Inc. Cell expansion
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US20190328869A1 (en) 2016-10-10 2019-10-31 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
CN110612344B (zh) 2017-03-31 2023-09-12 泰尔茂比司特公司 细胞扩增
EP3624851A1 (en) 2017-05-15 2020-03-25 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
JP7406377B2 (ja) 2017-05-15 2023-12-27 ヤンセン ファッシンズ アンド プリベンション ベーフェー 安定なウイルス含有組成物
AU2018287159B2 (en) 2017-06-21 2025-01-16 Transgene Personalized vaccine
EP3802841A1 (en) 2018-05-30 2021-04-14 Institute for Research in Biomedicine Engineering b lymphocytes by utilizing endogenous activation-induced cytidine deaminase
JP7437385B2 (ja) 2018-09-06 2024-02-22 バヴァリアン・ノルディック・アクティーゼルスカブ 保管が改善されたポックスウイルス組成物
KR20210094554A (ko) * 2018-11-23 2021-07-29 발네바 에스이 조류 줄기 세포를 포함하는 식품
CN119265099A (zh) * 2019-01-17 2025-01-07 勃林格殷格翰动物保健有限公司 用于禽类疫苗生产的无血清培养基及其用途
CN115243717A (zh) 2020-03-12 2022-10-25 巴法里安诺迪克有限公司 改善痘病毒稳定性的组合物
EP4170023A4 (en) * 2020-06-22 2024-09-11 Kolon Life Science, Inc. METHOD FOR MASS PRODUCTION OF VACCINIA VIRUS USING SUSPENSION CELLS
US20230256057A1 (en) 2020-07-13 2023-08-17 Transgene Treatment of immune depression
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5340740A (en) 1992-05-15 1994-08-23 North Carolina State University Method of producing an avian embryonic stem cell culture and the avian embryonic stem cell culture produced by the process
FR2726003B1 (fr) 1994-10-21 2002-10-18 Agronomique Inst Nat Rech Milieu de culture de cellules embryonnaires totipotentes aviaires, procede de culture de ces cellules, et cellules embryonnaires totipotentes aviaires
US5989805A (en) * 1995-10-27 1999-11-23 Board Of Trustees Operating Michigan State University Immortal avian cell line to grow avian and animal viruses to produce vaccines
US5672485A (en) 1996-08-13 1997-09-30 Regents Of The University Of Minnesota Immortalized cell lines for virus growth
DE69729839T2 (de) 1996-11-12 2005-07-21 Pfizer Inc. Attenuierter lebender Neospora Impfstoff
ATE312405T1 (de) * 2002-02-19 2005-12-15 Cellergy Ltd Elektrochemischer kondensator und dessen herstellung
FR2836924B1 (fr) * 2002-03-08 2005-01-14 Vivalis Lignees de cellules aviaires utiles pour la production de substances d'interet
US20040170646A1 (en) * 2002-12-13 2004-09-02 Aventis Pasteur, Inc. Production of ALVAC on avian embryonic stem cells
PL1646715T3 (pl) * 2003-07-22 2010-10-29 Valneva Wytwarzanie pokswirusów za pomocą linii adherentnych lub nieadherentnych komórek ptasich
EP1528101A1 (en) * 2003-11-03 2005-05-04 ProBioGen AG Immortalized avian cell lines for virus production

Also Published As

Publication number Publication date
AU2004257939B2 (en) 2008-06-05
US20100111999A1 (en) 2010-05-06
JP5416169B2 (ja) 2014-02-12
US20090239286A1 (en) 2009-09-24
US7771980B2 (en) 2010-08-10
JP2006527995A (ja) 2006-12-14
JP4787156B2 (ja) 2011-10-05
JP2011224009A (ja) 2011-11-10
AU2004257939A1 (en) 2005-01-27
US20060233834A1 (en) 2006-10-19
CA2531565A1 (en) 2005-01-27
CA2531565C (en) 2014-02-11
PT1646715E (pt) 2010-08-09
ES2345820T3 (es) 2010-10-04
EP1646715A1 (en) 2006-04-19
EP2143788A1 (en) 2010-01-13
ATE467678T1 (de) 2010-05-15
EP1646715B1 (en) 2010-05-12
KR101121971B1 (ko) 2012-03-09
WO2005007840A1 (en) 2005-01-27
SI1646715T1 (sl) 2010-09-30
PL1646715T3 (pl) 2010-10-29
KR20060057577A (ko) 2006-05-26
HK1091229A1 (en) 2007-01-12
DK1646715T3 (da) 2010-08-16
US7432101B2 (en) 2008-10-07

Similar Documents

Publication Publication Date Title
DE602004027141D1 (de) Produktion von poxviren mit adhärenten oder nicht adhärenten vogelzellinien
DE60320520D1 (de) Verfahren zur amplifikation von einem poxvirus in serumfreien verhältnissen
DK1483369T3 (da) Fuglecellelinier til fremstiling af stoffer af interesse
NO20054124L (no) Dyre-fri celle kultur metode
WO2010147395A3 (en) Medium composition comprising neuropeptide y for the generation, maintenance, prologned undifferentiated growth of pluripotent stem cells and method of culturing pluripotent stem cell using the same
ATE447010T2 (de) Verfahren zur produktion von viralen antigenen im grossmassstab
WO2007048089A3 (en) Multi-plasmid system for the production of influenza virus
WO2006029198A3 (en) Culturing human embryonic stem cells
MX2007005132A (es) Medios libres de proteina animal para cultivo de celulas.
BR112022010816A2 (pt) Métodos para melhoramento de crescimento celular com proteínas específicas de espécie ou específicas de gênero e aplicações dos mesmos
WO2009009797A3 (en) High fidelity restriction endonucleases
EA202091354A1 (ru) Способ культивирования клеток
AR114548A1 (es) Estrategias de cultivo celular para modular la glicosilación de proteínas
ATE553210T1 (de) Verfahren zur herstellung von l-threonin unter verwendung eines mikroorganismus mit inaktivierten galr gen.
DE60319599D1 (de) Verfahren zur differenzierung einer mesenchym-stammzelle zu einer nervenzelle sowie die nervenzelle eine neurodegenerative krankheit
EP4086994A4 (en) MEMBRANE-ELECTRODE ASSEMBLY, METHOD FOR MANUFACTURING SAME, AND FUEL CELL COMPRISING SAME
SG11201806843UA (en) Method for producing activated hepatocyte growth factor (hgf)
AR056840A1 (es) Celulas hospedantes y metodos de cultivo que implican la sobreexpresion de la man1c1
CN204259640U (zh) 高寒山区石蛙养殖保温装置
SG11201804754SA (en) Virus infection model, preparation method therefor, and utilization thereof
EP3783099C0 (en) METHOD FOR ISOLATION AND CULTURE OF NEURAL STEM CELLS WITH HIGH EFFICIENCY
BR112018015527A2 (pt) métodos para produção de vírus
EP3956463C0 (en) USE OF A CYTOFLUOROMETRY METHOD TO EVALUATE THE STABILITY AND VIABILITY OF A BIOMASS OF LYOPHILIZED BACTERIAL CELLS
EP4357447A3 (en) Serum-free medium for avian vaccine production and uses thereof
CN204418395U (zh) 一种应用于木结构中的防风扣件

Legal Events

Date Code Title Description
8364 No opposition during term of opposition